Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / If you've been following ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

Semaglutide and similar medications could be key players in bending the curve but enduring change ultimately hinges on a ...

Statements by Robert F. Kennedy Jr. and Elon Musk tap into a dispute over whether lifestyle changes or drugs are a better way to treat obesity.